What is Leerink Partnrs’ Estimate for KPTI Q1 Earnings?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst J. Chang anticipates that the company will post earnings per share of ($0.26) for the quarter. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.39) EPS.

A number of other analysts also recently issued reports on KPTI. StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Finally, Piper Sandler lifted their price target on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Trading Down 1.9 %

Shares of Karyopharm Therapeutics stock opened at $0.60 on Friday. The business’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.76. The firm has a market capitalization of $75.54 million, a P/E ratio of -0.59 and a beta of 0.06. Karyopharm Therapeutics has a 12 month low of $0.53 and a 12 month high of $1.70.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. The business had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.

Hedge Funds Weigh In On Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. lifted its stake in Karyopharm Therapeutics by 46.3% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock worth $4,274,000 after purchasing an additional 2,000,000 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares during the last quarter. GSA Capital Partners LLP lifted its stake in shares of Karyopharm Therapeutics by 80.6% in the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Karyopharm Therapeutics by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 1,392,314 shares of the company’s stock valued at $942,000 after acquiring an additional 36,922 shares during the last quarter. Finally, Jane Street Group LLC lifted its stake in shares of Karyopharm Therapeutics by 265.5% in the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after acquiring an additional 543,556 shares during the last quarter. 66.44% of the stock is currently owned by hedge funds and other institutional investors.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).